Topic: Public Citizen Foundation

FDA adds heart attack warning to Meridia diet pill

AP Features - 750 days ago
Abbott Laboratories on Thursday stopped marketing a weight loss pill in Europe after regulators there said the drug increases the risk of heart attack and stroke when used by heart disease patients.The European Medicines Agency advised doctors and pharmacists to stop using ...
Read More...

Consumer Advocate Asks FDA to Ban Weight Loss Pill

Drugs.com - 799 days ago
A consumer advocacy group is petitioning the government to ban the weight loss pill Meridia because a recent study suggests it increases risk of heart attack, stroke and death. A letter Thursday from Public Citizen calls on the Food and Drug Administration ...

Consumer advocate asks FDA to ban weight loss pill

AP Features - 799 days ago
A consumer advocacy group is petitioning the government to ban the weight loss pill Meridia because a recent study suggests it increases risk of heart attack, stroke and death.A letter Thursday from Public Citizen calls on the Food and Drug Administration to ...
Read More...

U.S. consumer group asks FDA to ban Abbott diet drug

Reuters US Online Report Health News - 799 days ago
WASHINGTON (Reuters) - Abbott Laboratories Inc's weight-loss drug Meridia should be banned immediately because of heart-related risks, a consumer group said on Thursday in a petition to U.S. regulators.Public Citizen said early results from a large international study called Scout added to ...
Read More...

Effient

Drugs.com - 981 days ago
Antiplatelet Medication Is Unsafe, Should Not Be Approved,Says Scientist Who Helped Develop the Drug . One of the scientists who holds a patent application for the blood clot inhibitor prasugrel hydrochloride, an acute coronary syndrome (ACS) treatment, wants the Food and Drug ...

FDA should halt Lilly bloodthinner review: U.S. group

Reuters US Online Report Health News - 982 days ago
* Group, researcher urge study of lower prasugrel dose* Dangerous bleeding, cancers a concern - group* Lilly, Daiichi confident in benefit-risk profile* Lilly shares down 1.5 pctBy Susan HeaveyWASHINGTON (Reuters) - U.S. regulators should halt their review of Eli Lilly and Co's ...
Read More...